UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of May, 2010

Commission File Number: 000-51310
 
XTL Biopharmaceuticals Ltd.
(Translation of registrant's name into English)

Kiryat Weizmann Science Park
3 Hasapir Street, Building 3, PO Box 370
Rehovot 76100, Israel
 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F                X                      Form 40-F                     

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes                                   No            X 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-    N/A  
 
 
 



Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated May 13, 2010 is hereby incorporated by reference into the registration statements on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23, 2007 , October 30, 2007 and August 15, 2008, respectively, and the registration statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.

XTL Biopharmaceuticals Extends the
Completion Date for the Bio-Gal Transaction

On April 26, 2010, XTL Biopharmaceuticals Ltd. (the “Company”) extended the completion date for the Bio-Gal transaction to June 30, 2010.  The remaining conditions for the completion of the share exchange in the transaction remained unchanged.  The Bio-Gal transaction was included in the Company’s annual financial statements published on the Tel Aviv Stock Exchange.  The Company’s annual financial statements were also translated from Hebrew to English and filed on Form 6-K with the Securities Exchange Commission on March 26, 2010.

The Company is diligently seeking the fulfillment of the remaining conditions.
 
 
 
 
 
 
-2-
 
 

Contact:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 612 7011, Email: ir@xtlbio.com

Cautionary Statement
Some of the statements included in this Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
 
 
 
 
 
 
 
 
 
 
 
-3-
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
XTL BIOPHARMACEUTICALS LTD.
  
       
Date: May 13, 2010
By:
/s/ David Grossman  
   
David Grossman
  
   
Chief Executive Officer
  
       
 
 
 
 
 
 
 
 
 
 

 
 
-4-